Supernus Pharma (SUPN) Misses Q3 EPS by 6c, Revenues Miss; Lowers FY19 Sales Views, Reports Topline Data from Ph. 3 Study of SPN-810
Tweet Send to a Friend
Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.54, $0.06 worse than the analyst estimate of $0.60. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
